NCT04665947View on ClinicalTrials.gov

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Metastatic Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.

Trial Locations (1)

95817

RECRUITING

University of California Davis, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER